Company Registration No: 199205095C Charity Registration No: 1036

IPC No: HEF0004/G

## ST LUKE'S HOSPITAL (Incorporated in Singapore)

## **DIRECTORS' STATEMENT** AND FINANCIAL STATEMENTS

31 MARCH 2025

## 31 MARCH 2025

CONTENTS	PAGE
Directors' Statement	1 - 3
Independent Auditor's Report	4 - 6
Statement of Financial Activities	7
Balance Sheet	8
Statement of Cash Flows	9
Statement of Financial Activities - Supplementary Schedules	10 - 13
Balance Sheet - Supplementary Schedules	14 - 15
Notes to the Financial Statements	16 - 44

#### DIRECTORS' STATEMENT FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

The directors are pleased to present their statement to the members together with the audited financial statements of St Luke's Hospital (the "Company") for the financial year ended 31 March 2025.

In the opinion of the directors,

- (a) the financial statements of the Company are drawn up so as to give a true and fair view of the balance sheet of the Company as at 31 March 2025 and of the financial performance and cash flows of the Company for the year then ended; and
- (b) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

#### 1 Directors

The directors of the Company in office at the date of this statement are:

Khoo Teng Cheong
Choo Eng Beng
Vice-Chairman
Kok Hei Mun Jonathan
Lee Kean Guan
Foong Daw Ching
Lim Beng Hoon Rosana
Ho Kuen Loon

Lea Chairman
Honorary Secretary
Honorary Treasurer

Ho Kuen Loon
Lau Tang Ching
Lim Huey Sheng
Lo Weng Fai Alex
Lum Kah Leong Jeffrey
Ng Bock Hon Danny
Ong Sor Boh Mabel
Yap Chin Huat Jason

#### 2 Directors' Interest in Shares, Debentures, Dividends and Share Options

The Company is limited by guarantee and does not have share capital. All matters relating to the issue of shares, debentures, dividends and share options are thus not applicable.

#### 3 Conflict of Interest

#### Statement of Purpose and Authority

Pursuant to the Code of Governance for Charities and Institutions of a Public Character (IPCs), the Board of Directors of the Company has established a policy on the avoidance of conflict of interest for the Company.

#### DIRECTORS' STATEMENT FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 3 Conflict of Interest (cont'd)

Statement of Purpose and Authority (cont'd)

The Company's basic policy on avoidance of conflict of interest rests on three premises:

- (a) Understanding what is a 'Conflict of Interest';
- (b) Declaration of Conflict of Interest; and
- (c) Abstention from decision making where Conflict of Interest has been declared or exists.

#### Definition of 'Conflict of Interest'

An operational definition of conflict of interest is when an individual is aware of "any interest in a transaction or arrangement that will affect his/her professional judgment to obtain the best value for the Company or to protect the interests of the Company."

Some of the more obvious conflicts of interest relate to:

- Procurement of goods or services (Contract with vendors);
- Hiring and personnel management pertaining to a close relationship with current board/committee members or decision makers;
- Provision of services or subsidies;
- Vested interest in other organisations that have dealings/relationships with the Company;
- Interest in joint ventures; and
- Major donors or representatives from major donors.

All key staff and directors must acknowledge that they understand the definition of 'Conflict of Interests' as above and they acknowledge that they will subscribe to the 'Avoidance of Conflict of Interest Policy' of the Company. This includes a declaration whenever there is a conflict or potential conflict and the individual will abstain from all decisions regarding that conflict of interest.

At the beginning of each financial year, the acknowledgement of the 'Conflict of Interest' notice is served to individuals and the 'Declaration of Conflict of Interest' notice at the end of each financial year. Members must declare the existence of a conflict of interest as soon as the individual becomes aware of the situation. To aid the members in discharging their responsibility in relation to the existence of a possible conflict of interest, members are required to declare their membership or significant involvement or interests in organisations that may pose a possible conflict of interest to the Company.

#### Abstention from Decision Making

Once an individual is aware of the existence of a conflict of interest, he/she must abstain from the decision making process pertaining to the possible conflict of interest. This means the individual should not influence the decision process. This does not necessarily prevent the individual from providing relevant and expert knowledge on the issue or participate in the discussion but he/she should only do so with wisdom so as not to influence the decision.

#### DIRECTORS' STATEMENT FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 4 Reserve Policy

The principal activity of the Company is to establish, carry on and maintain a hospital for the community including the elderly.

The Board has established a reserve policy ("Reserve Policy") for the Company. In setting the Reserve Policy, the Board feels that it is more reasonable to use net liquid assets available to meet expenditure obligations as a reserve measurement instead of unrestricted funds as some of these unrestricted funds may not represent cash or cash equivalent or liquid assets which can be used to meet its expenditure obligations. Net liquid assets (unrestricted) available to meet expenditure obligations (unrestricted) is calculated as total of investments in financial assets (unrestricted), trade and other receivables (unrestricted), cash and cash equivalents (unrestricted) less trade and other payables (unrestricted). The reserves of the Company provide financial stability and the means for the development of their operations and activities. The Company intends to maintain the reserves at a level sufficient for its operating needs and the Board regularly reviews the amount of reserves that are required to ensure that they are adequate to fulfill its continuing obligations. There are no changes to the reserve policy during the financial years ended 31 March 2025 and 2024.

#### 5 Independent Auditors

The independent auditors, Moore Stephens LLP, have expressed their willingness to accept reappointment as auditors.

On behalf of the Board of Directors

KHOO TENG CHEONG

Director

LEE KEAN GUAN

Director

Singapore 28 July 2025





#### INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF

# ST LUKE'S HOSPITAL (Incorporated in Singapore)

#### **Report on the Audit of the Financial Statements**

#### Opinion

We have audited the financial statements of St Luke's Hospital (the "Company"), which comprise the balance sheet of the Company as at 31 March 2025, the statement of financial activities and the statement of cash flows of the Company for the year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the financial statements are properly drawn up in accordance with the provisions of the Companies Act 1967 (the "Act"), the Charities Act 1994 (the "Charities Act") and other relevant regulations (the "Charities Act and Regulations") and Charities Accounting Standard ("CAS") so as to give a true and fair view of the financial position of the Company as at 31 March 2025 and of the financial performance and cash flows of the Company for the year ended on that date.

### Basis for Opinion

We conducted our audit in accordance with Singapore Standards on Auditing ("SSAs"). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Accounting and Corporate Regulatory Authority ("ACRA") *Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities* ("ACRA Code") together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Other Information

Management is responsible for the other information. The other information comprises the Directors' Statement.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.





#### INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF

# ST LUKE'S HOSPITAL (Incorporated in Singapore)

(cont'd)

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act, the Charities Act and Regulations and CAS, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance comprises the directors and their governing board. Their responsibilities include overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.





#### INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF

# ST LUKE'S HOSPITAL (Incorporated in Singapore)

(cont'd)

Auditor's Responsibilities for the Audit of the Financial Statements (cont'd)

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

#### Report on Other Legal and Regulatory Requirements

In our opinion, the accounting and other records required to be kept by the Company have been properly kept in accordance with the provisions of the Act, and the Charities Act and Regulations.

During the course of our audit, nothing has come to our attention that causes us to believe that during the financial year:

- (a) the Company has not used the donation moneys in accordance with its objectives as required under Regulation 11 of the Charities (Institutions of a Public Character) Regulations; and
- (b) the Company has not complied with the requirements of Regulation 15 of the Charities (Institutions of a Public Character) Regulations.

Moore Stephens LLP

Moore Stephens UP

Public Accountants and

**Chartered Accountants** 

Singapore 28 July 2025

## STATEMENT OF FINANCIAL ACTIVITIES

## FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

1 April 2024 to 31 March 2025					
	NT 4	Unrestricted	Restricted	Total	Total
	<u>Note</u>	<u>Funds</u> S\$	<u>Funds</u> S\$	2025 S\$	2024 S\$
INCOME		3.0	24	3.0	3.0
Income from generated funds:					
Voluntary income	4	6,349,754	5,847,548	12,197,302	13,548,212
Activities for generating funds	5	1,262,418	-	1,262,418	2,648,332
Investment income	6	1,907,213	93,845	2,001,058	1,980,954
Income from charitable activities	7	61,399,848	-	61,399,848	54,827,981
Other income	8	2,570,177	428	2,570,605	2,649,528
Total income		73,489,410	5,941,821	79,431,231	75,655,007
LESS: EXPENDITURES					
Costs of generating funds:					
Voluntary income	9	528,701	-	528,701	406,102
Fundraising activities	9	196,805	-	196,805	146,603
Charitable activities	10	66,079,947	4,929,940	71,009,887	64,838,909
Governance costs	11	1,902,440	-	1,902,440	1,587,000
Other expenditures	11	181,813	-	181,813	128,408
Total expenditures		68,889,706	4,929,940	73,819,646	67,107,022
Net income before tax expense	12	4,599,704	1,011,881	5,611,585	8,547,985
Tax expense	14				
Net income		4,599,704	1,011,881	5,611,585	8,547,985
Gross transfers between funds					
Gross transfers (to) funds		-	(1,993,401)	(1,993,401)	(2,561,829)
Gross transfers from funds		1,814,983	178,418	1,993,401	2,561,829
	20, 21	1,814,983	(1,814,983)	-	-
Net income/(loss) after funds transfer		6,414,687	(803,102)	5,611,585	8,547,985
Reconciliation of funds		(2.1.40.0.40	10.071.500	01.020.620	74.046.252
Total funds brought forward		62,149,040	18,871,589	81,020,629	74,846,353
Grant income Amortisation expenses net of depreciation		-	713,235	713,235	298,536
of property, plant and equipment credited to charitable activities	15	(11,969)	(2,827,860)	(2,839,829)	(2,672,245)
Total funds carried forward		68,551,758	15,953,862	84,505,620	81,020,629

The accompanying notes form an integral part of the financial statements.

## **BALANCE SHEET**

## **AS AT 31 MARCH 2025**

	Note	2025 S\$	2024 S\$
Non-Current Assets			
Property, plant and equipment	15	10,590,431	12,966,182
Investments in financial assets	16	1,005,500	1,005,500
	-	11,595,931	13,971,682
Current Assets			
Inventories, at cost		224,137	212,521
Trade and other receivables	17	18,747,337	19,848,857
Investments in financial assets	16	26,510,324	22,177,206
Cash and cash equivalents	18	45,553,419	40,234,440
1	-	91,035,217	82,473,024
	-		
Less: Current Liabilities			
Trade and other payables	19	18,125,528	15,424,077
Net Current Assets	-	72,909,689	67,048,947
<b>Total Assets less Total Liabilities</b>	=	84,505,620	81,020,629
Funds of Charity			
Unrestricted Funds			
Unrestricted income funds	20	51,000,571	47,776,910
Designated funds	20	17,551,187	14,372,130
	-	68,551,758	62,149,040
Restricted Funds			
Restricted income funds	21	15,953,862	18,871,589
Total Charity Funds		84,505,620	81,020,629
•	•	, ,	

## STATEMENT OF CASH FLOWS

## FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

	<u>Note</u>	2025 S\$	2024 S\$
Cash Flows from Operating Activities		Бψ	Σψ
Net income before tax expense		5,611,585	8,547,985
Adjustments for:		0,011,000	0,0 . 7,5 00
Depreciation of property, plant and equipment	15	5,386,879	5,154,591
Interest income	6	(1,802,202)	(1,456,640)
Dividend income	6	(26,147)	(18,114)
Amortisation of building fund	15	(427,156)	(427,153)
Amortisation of building expansion fund	15	(1,678,822)	(1,606,080)
Amortisation of Community Silver Trust capital grant	15	(721,882)	(633,040)
Amortisation of new project fund	15	(11,969)	(5,972)
Loss on write off of property, plant and equipment	12	1,701	281
Gain on disposal of investments in financial assets	6	(76,000)	(34,365)
Impairment loss on investments in financial assets	16	78,091	29,829
Reversal of impairment loss on investments in		,	,
financial assets	6	(96,709)	(471,835)
Provision for doubtful debts	12	44,882	4,416
Write back of provision for doubtful debts	12	(1,782)	(51)
Bad debt written off	12	1,792	1,376
Operating cash flows before changes in working capital		6,282,261	9,085,228
Inventories		(11,616)	(28,044)
Trade and other receivables		1,149,618	(285,792)
Trade and other payables		2,701,451	1,132,933
Net cash flows generated from operating activities		10,121,714	9,904,325
Cash Flows from Investing Activities			
Acquisition of investments in financial assets	16	(19,804,655)	(13,662,412)
Acquisition of property, plant and equipment	15	(3,012,829)	(3,019,256)
Proceeds from disposal of investments in financial assets		3,466,155	2,530,224
Proceeds from redemption of debt securities	16	12,100,000	8,900,000
Interest received		1,709,212	1,404,575
Dividend received		26,147	18,114
Net cash flows used in investing activities		(5,515,970)	(3,828,755)
			_
Cash Flows from Financing Activities			
Funds received from CST capital grant	21(iv)	100,195	-
Funds received for building expansion fund	21(ii)	613,040	298,536
Net cash flows generated from financing activities		713,235	298,536
-			
Net increase in cash and cash equivalents		5,318,979	6,374,106
Cash and cash equivalents at the beginning of the year		40,234,440	33,860,334
Cash and cash equivalents at the end of the year	18	45,553,419	40,234,440
·			

The accompanying notes form an integral part of the financial statements.

## STATEMENT OF FINANCIAL ACTIVITIES - SUPPLEMENTARY SCHEDULES

## FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

		Unrestricted Funds						Restricted Funds							
1 April 2024 to 31 March 2025	<u>Note</u>	Unrestricted income fund S\$	Asset replacement fund S\$	New project fund S\$	Talent management <u>fund</u> S\$	Bicentennial community fund S\$	Sub-total S\$	Building fund - General S\$	Building expansion fund S\$	Community Silver Trust <u>fund</u> S\$	Community Silver Trust capital grant S\$	Other funds S\$	Sub-total S\$	Total 2025 S\$	Total 2024 S\$
INCOME Income from generated funds:															
Voluntary income	4	6,349,754	_				6,349,754			4,537,456	_	1,310,092	5,847,548	12,197,302	13,548,212
Activities for generating funds	5	1,262,418	_	_	_	_	1,262,418	_	_	-	_	1,510,052	5,017,510	1,262,418	2,648,332
Investment income	6	1,474,506	156,683	167,517	84,977	23,530	1,907,213	_	_	43,656	_	50,189	93,845	2,001,058	1,980,954
Income from charitable activities	7	61,399,848	-	-		-	61,399,848	_	_		_	-	-	61,399,848	54,827,981
Other income	8	2,570,177	_	_	_	_	2,570,177	_	_	_	_	428	428	2,570,605	2,649,528
Total income		73,056,703	156,683	167,517	84,977	23,530	73,489,410	-	-	4,581,112	-	1,360,709	5,941,821	79,431,231	75,655,007
LESS: EXPENDITURES															
Costs of generating funds:															
Voluntary income	9	528,701	-	-	-	-	528,701	-	-	-	-	-	-	528,701	406,102
Fundraising activities	9	196,805	-	-	-	-	196,805	-	-	-	-	-	-	196,805	146,603
Charitable activities	10	65,838,266	-	-	165,581	76,100	66,079,947	-	-	3,352,191	-	1,577,749	4,929,940	71,009,887	64,838,909
Governance costs	11	1,902,440	-	-	-	-	1,902,440	-	-	-	-	-	-	1,902,440	1,587,000
Other expenditures	11	181,813	-	-	-	-	181,813	-	-	-	-	-	-	181,813	128,408
Total expenditures		68,648,025	-	-	165,581	76,100	68,889,706	-	-	3,352,191	-	1,577,749	4,929,940	73,819,646	67,107,022
Net income before tax expense	12	4,408,678	156,683	167,517	(80,604)	(52,570)	4,599,704	-	-	1,228,921	-	(217,040)	1,011,881	5,611,585	8,547,985
Tax expense	14		-	-	-	-	-	-	-	-	-	-	-	-	-
Net income		4,408,678	156,683	167,517	(80,604)	(52,570)	4,599,704	-	-	1,228,921	-	(217,040)	1,011,881	5,611,585	8,547,985
Gross transfer between funds															
Gross transfers (to) funds		(3,000,000)	-	2,000,000	1,000,000	-	-	-	-	(1,993,401)	_	-	(1,993,401)	(1,993,401)	(2,561,829)
Gross transfers from funds		1,814,983	-	-	-	-	1,814,983	-	-		178,418	-	178,418	1,993,401	2,561,829
	20, 21	(1,185,017)	-	2,000,000	1,000,000	-	1,814,983	-	-	(1,993,401)	178,418	-	(1,814,983)	-	-
Net income after funds transfer		3,223,661	156,683	2,167,517	919,396	(52,570)	6,414,687			(764,480)	178,418	(217,040)	(803,102)	5,611,585	8,547,985

The accompanying notes form an integral part of the financial statements.

## STATEMENT OF FINANCIAL ACTIVITIES - SUPPLEMENTARY SCHEDULES

## FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

(cont'd)

,			Unrestricted Funds Restricted Funds								<u>-</u>				
1 April 2024 to 31 March 2025 (cont'd)	Note	Unrestricted income Fund, S\$	Asset replacement fund S\$	New project fund S\$	Talent management <u>fund</u> S\$	Bicentennial community fund S\$	Sub-total S\$	Building fund - General S\$	Building expansion fund S\$	Community Silver Trust <u>fund</u> S\$	Community Silver Trust capital grant S\$	Other funds S\$	Sub-total S\$	Total <u>2025</u> S\$	Total <u>2024</u> S\$
Reconciliation of funds															
Total funds brought forward		47,776,910	6,354,922	5,274,994	2,324,315	417,899	62,149,040	1,032,289	4,215,169	10,621,609	1,528,106	1,474,416	18,871,589	81,020,629	74,846,353
Grant received during the financial year Amortisation expenses net of depreciation of property, plant and equipment credited to charitable		-	-	-	-	-	-	-	613,040	-	100,195	-	713,235	713,235	298,536
activities	15	-	-	(11,969)	-	-	(11,969)	(427,156)	(1,678,822)	-	(721,882)	-	(2,827,860)	(2,839,829)	(2,672,245)
Total funds carried forward		51,000,571	6,511,605	7,430,542	3,243,711	365,329	68,551,758	605,133	3,149,387	9,857,129	1,084,837	1,257,376	15,953,862	84,505,620	81,020,629

## STATEMENT OF FINANCIAL ACTIVITIES - SUPPLEMENTARY SCHEDULES

## FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

(cont'd)

(cont u)				Unrestric	ted Funds				Restricted Funds						
1 April 2023 to 31 March 2024	<u>Note</u>	Unrestricted income fund S\$	Asset replacement fund S\$	New project <u>fund</u> S\$	Talent management fund S\$	Bicentennial community <u>fund</u> S\$	Sub-total S\$	Building fund - General S\$	Building expansion fund S\$	Community Silver Trust <u>fund</u> S\$	Community Silver Trust capital grant S\$	Other funds S\$	Sub-total S\$	Total 2024 S\$	Total 2023 S\$
INCOME Income from generated funds:															
Voluntary income	4	5,707,797			468,600		6,176,397			6,314,670		1,057,145	7,371,815	13,548,212	14,203,382
Activities for generating funds	5	2,648,332	_	_	-	_	2.648.332	_	_	0,511,070	_	1,037,113		2,648,332	1,439,065
Investment income	6	1,410,823	186,569	133,406	101,944	17,899	1,850,641	-	_	87,415	-	42,898	130,313	1,980,954	972,119
Income from charitable activities	7	54,827,981	-	-	-		54,827,981	_	_	-	_	.2,0,0	-	54,827,981	50,895,077
Other income	8	2,540,070	_	_	_	_	2,540,070	_	_	_	_	109,458	109,458	2,649,528	2,102,542
Total income		67,135,003	186,569	133,406	570,544	17,899	68,043,421	-	-	6,402,085	-	1,209,501	7,611,586	75,655,007	69,612,185
LESS: EXPENDITURES Costs of generating funds:															
Voluntary income	9	406,102	_	_	_	_	406,102	_	_	_	_	_	_	406,102	495,615
Fundraising activities	9	146,603	_	_	_	_	146,603	_	_	_	_	_	_	146,603	110,530
Charitable activities	10	60,860,576	_	-	167,250	-	61,027,826	-	-	2,701,691	-	1,109,392	3,811,083	64,838,909	61,087,907
Governance costs	11	1,587,000	_	-	, , , , , , , , , , , , , , , , , , ,	-	1,587,000	-	-	· · · · -	-	-	-	1,587,000	1,375,788
Other expenditures	11	128,408	-	-	-	-	128,408	-	-	-	-	-	-	128,408	695,539
Total expenditures		63,128,689	-	-	167,250	-	63,295,939	=-	-	2,701,691	-	1,109,392	3,811,083	67,107,022	63,765,379
Net income before tax expense Tax expense	12 14	4,006,314	186,569	133,406	403,294	17,899	4,747,482	- -	-	3,700,394	- -	100,109	3,800,503	8,547,985	5,846,806
Net income		4,006,314	186,569	133,406	403,294	17,899	4,747,482	-	-	3,700,394	-	100,109	3,800,503	8,547,985	5,846,806
Gross transfer between funds															
Gross transfers (to) funds		-	-	-	-	-	-	-	-	(2,561,829)	-	-	(2,561,829)	(2,561,829)	(2,184,556)
Gross transfers from funds		2,525,868	-	-	-	-	2,525,868	-	-	-	35,961	-	35,961	2,561,829	2,184,556
2	20, 21	2,525,868	-	-	-	-	2,525,868	-	-	(2,561,829)	35,961	-	(2,525,868)	-	
Net income after funds transfer		6,532,182	186,569	133,406	403,294	17,899	7,273,350	-	-	1,138,565	35,961	100,109	1,274,635	8,547,985	5,846,806

The accompanying notes form an integral part of the financial statements.

## STATEMENT OF FINANCIAL ACTIVITIES - SUPPLEMENTARY SCHEDULES

## FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

(cont'd)

,				Unrestric	Unrestricted Funds Restricted Funds							<u>-</u>			
1 April 2023 to 31 March 2024 (cont'd)	Note	Unrestricted income fund S\$	Asset replacement fund S\$	New project fund S\$	Talent management <u>fund</u> S\$	Bicentennial community fund S\$	Sub-total S\$	Building fund <u>- General</u> S\$	Building expansion <u>fund</u> S\$	Community Silver Trust <u>fund</u> S\$	Community Silver Trust capital grant S\$	Other funds S\$	Sub-total S\$	Total 2024 S\$	Total 2023 S\$
Reconciliation of funds															
Total funds brought forward		41,244,728	6,168,353	5,147,560	1,921,021	400,000	54,881,662	1,459,442	5,522,713	9,483,044	2,125,185	1,374,307	19,964,691	74,846,353	71,181,177
Grant received during the financial year Amortisation expenses net of depreciation of property, plant and equipment credited to charitable		-	-	=	-	-	=	-	298,536	-	-	=	298,536	298,536	442,984
activities	15	-	-	(5,972)	-	-	(5,972)	(427,153)	(1,606,080)	-	(633,040)	-	(2,666,273)	(2,672,245)	(2,624,614)
Total funds carried forward		47,776,910	6,354,922	5,274,994	2,324,315	417,899	62,149,040	1,032,289	4,215,169	10,621,609	1,528,106	1,474,416	18,871,589	81,020,629	74,846,353

## BALANCE SHEET - SUPPLEMENTARY SCHEDULES AS AT 31 MARCH 2025

			Unrestrict	ed Funds			Restricted Funds						
<u>2025</u>	Unrestricted income fund S\$	Asset replacement <u>fund</u> S\$	New project <u>fund</u> S\$	Talent management <u>fund</u> S\$	Bicentennial community fund S\$	Sub-total S\$	Building fund <u>- General</u> S\$	Building expansion <u>fund</u> S\$	Community Silver Trust <u>fund</u> S\$	Community Silver Trust capital grant S\$	Other <u>funds</u> S\$	Sub-total S\$	<u>Total</u> S\$
Non-Current Assets													
Property, plant and equipment	5,226,647	-	-	-	-	5,226,647	605,133	3,149,387	-	1,084,837	524,427	5,363,784	10,590,431
Investments in financial assets	1,005,500	-	-	-	-	1,005,500	-	-	-	-	-	-	1,005,500
	6,232,147	-	-	-	-	6,232,147	605,133	3,149,387	-	1,084,837	524,427	5,363,784	11,595,931
Current Assets Inventories, at cost Trade and other receivables Investments in financial assets	224,137 6,213,762 26,510,324	- - -	- - -	- - -	- - -	224,137 6,213,762 26,510,324	- - -	- - -	10,852,126	- - -	- 1,681,449 -	12,533,575	224,137 18,747,337 26,510,324
Cash and cash equivalents	27,593,558	6,511,605	7,430,542	3,243,711	365,329	45,144,745	-	_	(994,997)	-	1,403,671	408,674	45,553,419
	60,541,781	6,511,605	7,430,542	3,243,711	365,329	78,092,968	-	-	9,857,129	-	3,085,120	12,942,249	91,035,217
Less: Current Liabilities Trade and other payables	15,773,357	-	-	-	-	15,773,357		-	-	-	2,352,171	2,352,171	18,125,528
Net Current Assets	44,768,424	6,511,605	7,430,542	3,243,711	365,329	62,319,611	-	-	9,857,129	-	732,949	10,590,078	72,909,689
<b>Total Assets less Total Liabilities</b>	51,000,571	6,511,605	7,430,542	3,243,711	365,329	68,551,758	605,133	3,149,387	9,857,129	1,084,837	1,257,376	15,953,862	84,505,620

The accompanying notes form an integral part of the financial statements.

## BALANCE SHEET - SUPPLEMENTARY SCHEDULES AS AT 31 MARCH 2025

(cont'd)

·			Unrestric	ted Funds			Restricted Funds						
<u>2024</u>	Unrestricted income fund S\$	Asset replacement fund S\$	New project <u>fund</u> S\$	Talent management <u>fund</u> S\$	Bicentennial community fund S\$	Sub-total S\$	Building fund - General S\$	Building expansion fund S\$	Community Silver Trust <u>fund</u> S\$	Community Silver Trust capital grant S\$	Other funds S\$	Sub-total S\$	Total S\$
Non-Current Assets													
Property, plant and equipment	5,666,196	-	-	-	-	5,666,196	1,032,289	4,215,169	-	1,528,106	524,422	7,299,986	12,966,182
Investments in financial assets	1,005,500	-	-	-	-	1,005,500	-	-	-	-	-	-	1,005,500
<u>-</u>	6,671,696	-	-	-	-	6,671,696	1,032,289	4,215,169	-	1,528,106	524,422	7,299,986	13,971,682
Current Assets													
Inventories, at cost	212,521	-	-	-	-	212,521	-	-	-	-	-	-	212,521
Trade and other receivables	6,608,270	-	-	-	-	6,608,270	-	-	11,724,222	-	1,516,365	13,240,587	19,848,857
Investments in financial assets	22,177,206	<del>-</del>	<u>-</u>	<u>-</u>		22,177,206	-	-	-	-	<u>-</u>		22,177,206
Cash and cash equivalents	26,079,572	6,354,922	5,274,994	2,324,315	417,899	40,451,702	-		(1,102,613)	-	885,351	(217,262)	40,234,440
-	55,077,569	6,354,922	5,274,994	2,324,315	417,899	69,449,699	-	-	10,621,609	-	2,401,716	13,023,325	82,473,024
Less: Current Liabilities													
Trade and other payables	13,972,355	-	-	-	-	13,972,355	-	-	-	-	1,451,722	1,451,722	15,424,077
Net Current Assets	41,105,214	6,354,922	5,274,994	2,324,315	417,899	55,477,344	_	_	10,621,609	_	949,994	11,571,603	67,048,947
1100 04110110 1155005	11,100,214	0,557,722	3,2,1,,,,,	2,327,313	117,022	55,177,544			10,021,007		2 12,227	11,5 / 1,005	07,010,747
Total Assets less Total Liabilities	47,776,910	6,354,922	5,274,994	2,324,315	417,899	62,149,040	1,032,289	4,215,169	10,621,609	1,528,106	1,474,416	18,871,589	81,020,629

#### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

#### 1 General Information

St Luke's Hospital (the "Company") is a public company limited by guarantee, incorporated and domiciled in Singapore. The registered office of the Company and its principal place of business is at 2 Bukit Batok Street 11, Singapore 659674.

The principal activity of the Company is to establish, carry on and maintain a hospital for the community including the elderly.

These financial statements were approved and authorised for issue in accordance with a resolution of the Board of Directors of the Company (the "Board") on the date of the Directors' Statement.

### 2 Material Accounting Policy Information

#### (a) Basis of Preparation

The financial statements of the Company have been prepared in accordance with the provisions of the Companies Act 1967 (the "Act"), the Charities Act 1994 (the "Charities Act") and other relevant regulations (the "Charities Act and Regulations") and Charities Accounting Standard ("CAS").

The accounting policies of the Company are consistent with the requirements of CAS and are applied consistently to similar transactions, other events and conditions. The financial statements have been prepared on the historical basis, except as disclosed in the material accounting policy information.

The preparation of financial statements in conformity with CAS requires management to exercise its judgment in the process of applying the Company's accounting policies. It also requires the use of accounting estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the financial period. Although these estimates are based on management's best knowledge of current events and actions, actual results may ultimately differ from those estimates. The areas involving a higher degree of judgement or complexity are disclosed in Note 3 to the financial statements.

#### (b) Foreign Currencies

#### Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the Company operates (the "functional currency"). The financial statements of the Company are presented in Singapore Dollar ("S\$"), which is the Company's functional currency, as it best reflects the economic substance of the underlying transactions events and circumstances relevant to the Company.

#### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 2 Material Accounting Policy Information (cont'd)

#### (b) Foreign Currencies (cont'd)

#### Transactions and balances

Transactions in a currency other than the Company's functional currency ("foreign currency") are translated into the Company's functional currency using the exchange rates prevailing at the dates of the transactions. Currency translation gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in net income or expenditure in the statement of financial activities.

#### (c) Fund Accounting

Monies received for specific purposes, including transfers from the general fund, are credited directly to the respective fund financial statements. These include restricted funds and unrestricted funds. Restricted funds are funds held by the Company that can only be applied for specific purposes. These funds are subject to specific trusts which may be declared by the donors or with their authority or created through legal process but are still within the wider objects of the Company. Unrestricted funds are expendable at the discretion of the Board in furtherance of the Company's objects. Designated fund is part of the unrestricted funds earmarked for a particular project. The designation is for administrative purpose only and does not restrict the Board's discretion to apply the fund.

Income and expenditure relating to specific funds are accounted for directly in the funds to which they relate. Common expenses, if any, are allocated on a reasonable basis to the funds based on a method suitable to this common expense. Assets and liabilities of the specific funds are pooled in the balance sheet.

Funds received for specific purposes such as purchase of depreciable assets are taken to relevant restricted fund account. This relevant restricted fund will be reduced over the useful life of the asset in line with its depreciation.

If its use is unrestricted, the governing board members may consider creating a designated fund reflecting the value of the asset. Likewise, depreciation will be debited to the relevant designated funds where the asset is held, if this is the intention.

#### (d) Property, Plant and Equipment

Property, plant and equipment are initially stated at cost. Subsequently, property, plant and equipment are stated at cost less accumulated depreciation. The cost of an item of property, plant and equipment includes its purchase price and any cost that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Irrecoverable GST allocated to property, plant and equipment and to other items shall be included in their cost where it meets the criteria for capitalisation and significance. The projected cost of dismantlement, removal or restoration is also included as part of the cost of property, plant and equipment if the obligation for the dismantlement, removal or restoration is incurred as a consequence of acquiring or using the asset.

#### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 2 Material Accounting Policy Information (cont'd)

#### (d) Property, Plant and Equipment (cont'd)

The cost of an item of property, plant and equipment is recognised as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. When significant parts of property, plant and equipment are required to be replaced in intervals, the cost of replacing such an item when that cost is incurred is added to the carrying amount of the item if the recognition criteria are met. The cost of day-to-day servicing of an item of property, plant and equipment is recognised as expenditure in the statement of financial activities in the period in which the costs are incurred. Property, plant and equipment shall not be revalued and are not required to be assessed for impairment.

Depreciation is calculated using the straight-line method to allocate their depreciable amounts over their estimated useful lives as follows:

Leasehold building - 10 - 30 years
Furniture and office equipment - 5 years
Computers - 3 years
Hospital equipment - 5 years

No depreciation is provided on building under construction.

The depreciation charge for each period is recognised as expenditure in the statement of financial activities unless another section of the CAS requires it to be included in the carrying amount of another asset. The residual values, estimated useful lives and depreciation method of property, plant and equipment are reviewed and adjusted, as appropriate, at each reporting date. The effects of any revisions are recognised in the statement of financial activities for the financial year in which the changes arise. The carrying amount of the property, plant and equipment at the date of revision or changes is depreciated over the revised remaining useful lives.

#### (e) Investments in Financial Assets

Investments in financial assets are investments in debt and equity instruments which are recognised when it becomes a party to the contractual provisions of the instrument. They are included in non-current assets unless management holds the assets primarily for the purpose of trading or expects to realise the assets within twelve months after the reporting date.

Investments in financial assets are initially recognised at the transactions price excluding transaction cost, if any. Transaction costs are recognised as expenditure in the statement of financial activities as incurred after initial measurement. Investments in financial assets are subsequently measured at cost less any accumulated impairment losses. Investments in financial assets are not measured at fair value subsequent to initial recognition.

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 2 Material Accounting Policy Information (cont'd)

#### (f) Trade and Other Receivables

Trade and other receivables excluding prepayments are initially recognised at their transactions price, excluding transaction costs, if any. Transactions costs are recognised as expenditure in the statement of financial activities as incurred. Prepayments are initially recognised at the amount paid in advance for the economic resources expected to be received in the future.

After initial recognition, trade and other receivables excluding prepayments are subsequently measured at cost less any accumulated impairment losses. Prepayments are subsequently measured at the amount paid less the economic resources received or consumed during the financial year.

Financial assets (consisting of "cash and cash equivalents", and "trade and other receivables" excluding prepayments), are derecognised when the contractual rights to receive cash flows from the assets have expired or have been transferred and the Company have transferred substantially all risks and rewards of ownership. On derecognition of financial assets in its entirely, the difference between the carrying amount and the sum of the consideration received are recognised in the statement of financial activities.

#### (g) Impairment of Financial Assets

The Company assess at each reporting date whether there is objective evidence that a financial asset or a group of financial assets is impaired and recognises an impairment loss (i.e. expenditure) immediately in the statement of financial activities when such evidence exists.

An allowance for impairment is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables.

To determine whether there is objective evidence that an impairment loss has been incurred, the Company consider assessable data that come to the attention of the Company.

In the case of trade and other receivables, the amount of impairment loss is the difference between the financial asset's carrying amount and the undiscounted future cash flows, excluding unearned interest of interest-bearing assets that the Company expect to receive from the financial assets.

For an equity investment, the impairment loss is the difference between the carrying amount of the investment and the best estimate (which will necessarily be an approximation) of the amount (which might be zero) that the Company would receive for the investment if it was to be sold at the reporting date. For all other financial assets, the impairment loss is the difference between the carrying amount of the financial asset and the undiscounted future cash flows (excluding unearned interest in the case of an interest-bearing financial asset) that the charity expects to receive from the financial asset.

The recognised impairment loss is subsequently reversed if the amount of the impairment loss decreases and the decrease is related objectively to an event occurring after the impairment is recognised. The reversal shall not result in a carrying amount of the financial assets, net of any allowance account that exceeds what the carrying amount would have been had the impairment not previously been recognised. The reversal of impairment loss is recognised in the statement of financial activities.

#### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 2 Material Accounting Policy Information (cont'd)

#### (h) Inventories

Inventories comprising pharmaceutical and surgical products, linens and pyjamas are stated at the lower of cost and net realisable value. Cost is determined on a weighted average cost basis and includes all costs in bringing the inventories to their present location and condition. The net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.

#### (i) Cash and Cash Equivalents

Cash and cash equivalents comprise cash on hand and at bank and fixed deposits which are short term, highly liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value. These include cash and cash equivalents held under restricted funds, the use of which is subject to the relevant restricted funds' operating terms.

### (j) Trade and Other Payables

Trade and other payables (excluding accruals), are recognised at their transaction price, excluding transaction costs, if any, both at initial recognition and at subsequent measurement. Transaction costs are recognised as expenditure in the statement of financial activities as incurred. Accruals are recognised at the best estimate of the amount payable.

Financial liabilities are recognised on the balance sheet when, and only when the Company becomes a party to the contractual provisions of the financial instrument. The Company derecognises financial liabilities when, and only when, the Company's obligations are discharged, cancelled or expired.

#### (k) Income Recognition

Income including donations, gifts and grants that provide core funding or are of a general nature are recognised when there is (a) entitlement (b) certainty and (c) sufficient reliability of measurement. Such income is only deferred when: the donor specifies that the grant of donation must only be used in future accounting periods; or the donor has imposed conditions which must be met before the Company have unconditional entitlement.

#### **Donations**

Donations and corporate cash sponsorships are accounted for as income when received, except for committed donations and corporate cash sponsorships that are recorded when the commitments are fulfilled.

Cash donations which are still in collection containers at public and other premises or are in transit to the Company are not recognised as income until they have been received and accounted for by the Company. Donations are recognised on a receipt basis.

#### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 2 Material Accounting Policy Information (cont'd)

#### (k) Income Recognition (cont'd)

#### Donations (cont'd)

No value is ascribed to volunteer services, donated services, assets donated for continuing use or similar donations-in-kind, unless the benefit to the Company is reasonably quantifiable and measurable in which case an equivalent amount is recorded in expenditure, or capitalised as appropriate. Donations-in-kind received for continuing use are capitalised and included in the balance sheet at a reasonable estimate or in the event that it is not practicable to do so, a nominal value of S\$1 is assigned to capitalise the useable assets.

#### Grants

Grants received to cover a particular expenditure or programme are accounted for as income upon receipt of notification of the grant award and when the criteria of entitlement, certainty and measurability are met. When conditions are attached, they must be fulfilled before the Company have unconditional entitlement to the income. The income is deferred as a liability where uncertainty exists as to whether the Company can meet the conditions and is recognised as income when there is sufficient evidence that the conditions imposed can be met.

#### **Others**

Items received which are donated for resale, distribution or consumption are not recorded when received as it is usually not practical to ascertain the value of the items involved.

Interest income is recognised on a time proportion basis using the effective interest method.

Dividend income is recognised when the right to receive payment is established.

#### (l) Expenditures

All expenditures are accounted for on an accrual basis and have been classified under headings that aggregate all costs related to that activity. Documented procedures and delegations of authority are in place for procurement and payment procedures.

#### Costs of generating funds

The costs of generating funds are those costs attributable to generating income for the Company, other than those costs incurred in undertaking charitable activities in furtherance of the Company's objects.

#### Charitable activities

Expenditure on charitable activities comprises all costs incurred in the pursuit of the charitable objects of the Company. Those costs, where not wholly attributable, are apportioned between the categories of charitable expenditure. The total costs of each category of charitable expenditure therefore include an apportionment of support cost, where possible.

#### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 2 Material Accounting Policy Information (cont'd)

(l) Expenditures (cont'd)

#### Governance costs

Governance costs include the costs of governance arrangements, which relate to the general running of the Company as opposed to the direct management functions inherent in generating funds, service delivery and programme or project work. Expenditure on the governance of the charity will normally include both direct and related support costs which include internal and external audit, apportioned manpower costs and general costs in supporting the governance activities, legal advice for governing board members, and costs associated with constitutional and statutory requirements.

#### Support costs

Support costs are costs incurred in supporting income generation activities such as fundraising, and in supporting the governance of the charity. Support costs do not in themselves constitute an activity; instead they enable output-creating activities to be undertaken. Support costs include office functions such as key and general management, information technology, human resources, and financing and these are apportioned to the relevant activity cost category they support.

#### Other expenditures

Other expenditures include the payment of any expenditure that the Company have not been able to analyse within the main expenditure categories. Documented procedures and delegations of authority are in place for procurement and payment procedures.

## (m) Employee Benefits

#### Defined contribution plans

Defined contribution plans are post-employment benefit plans under which the Company pay fixed contributions such as the Central Provident Fund, and will have no legal or constructive obligation to pay further contributions if any of the funds do not hold sufficient assets to pay all employee benefits relating to employee services in the current period and preceding financial years. The Company's contributions to defined contribution plans are recognised in the financial year to which they relate.

#### Employee leave entitlements

Employee entitlements to annual leave and long service leave are recognised when they accrue to employees. An accrual is made for the estimated liability for annual leave and long-service leave as a result of services rendered by employees up to the reporting date.

#### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 2 Material Accounting Policy Information (cont'd)

#### (n) Operating Leases

Leases of assets in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are taken to the statement of financial activities on a straight-line basis over the year of the lease. When an operating lease is terminated before the lease period has expired, any payment required to be made to the lessor by way of penalty is recognised as an expense in the year in which termination takes place.

#### (o) Income Tax

The Company is an approved charity under the Charities Act and an Institution of a Public Character ("IPC") under the Income Tax Act 1947 (the "Income Tax Act"). No provision for taxation has been made in the financial statements as the Company is a registered charity with income tax exemption.

#### 3 Critical Accounting Estimates, Assumptions and Judgments

Estimates, assumptions and judgments are continually being evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results.

#### (a) Key Sources of Estimation Uncertainty

In the preparation of these financial statements, there were no critical accounting estimates and assumptions made in the process of applying the Company's accounting policies that have a significant effect on the amounts recognised in the financial statements at the reporting date that have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities within the next financial year.

#### (b) Critical Judgments made in Applying Accounting Policies

The critical judgments that are expected to have a significant effect on the amounts recognised in the financial statements are discussed below.

#### Impairment of trade and other receivables (excluding prepayments)

The Company assesses at each reporting date whether there is objective evidence that trade and other receivables (excluding prepayments) have been impaired. Provision for doubtful debts is calculated based on a review of the current status of existing receivables and historical collections experience. Such provision is adjusted periodically to reflect the actual and anticipated experience.

During the financial year ended 31 March 2025, the Company recognised a provision for doubtful debts for trade receivables amounting to S\$44,882 (2024: S\$4,416). The carrying amount of the Company's trade receivables and other receivables (excluding prepayments) at the reporting date are set out in Note 17.

#### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 3 Critical Accounting Estimates, Assumptions and Judgments (cont'd)

(b) Critical Judgments made in Applying Accounting Policies (cont'd)

#### Apportionment of costs

In determining the apportionment of costs between the governance costs, charitable activity, and fundraising activity categories, management has considered the materiality of the cost amounts involved and apportioned the costs based on the expenditure incurred directly in undertaking an activity, amount of time spent in an activity, floor area occupied by an activity and the number of staff employed within an activity.

Support costs incurred in supporting voluntary income generation are apportioned to the costs of generating funds – voluntary income category. Management has exercised their judgment and is satisfied that the bases for apportionment are appropriate to the cost concerned and to the Company's particular circumstances. The bases for apportionment adopted by the Company were consistent between financial periods.

During the financial year ended 31 March 2025, the Company has costs of generating funds amounting to \$\$725,506 (2024: \$\$552,705), costs of charitable activities amounting to \$\$71,009,887 (2024: \$\$64,838,909), governance costs amounting to \$\$1,902,440 (2024: \$\$1,587,000) and other expenditures amounting to \$\$181,813 (2024: \$\$128,408).

#### Impairment assessment of investments in financial assets

At the end of each reporting period, management of the Company assesses whether there is objective evidence of impairment of the investments in financial assets. When considering objective evidence of impairment, the Company considers both internal (e.g. observable data indicating that there has been a measurable decrease in the estimated cash flows since the initial recognition) and external sources (e.g. significant changes with an adverse effect in the market, economic or legal environment in which the funds operate).

Management has exercised their judgement in evaluating any indicators of impairment or reversal of previously recognised impairment and guidelines have been established to facilitate the exercise of judgement in determining the risk characteristics and estimates of future cash flows of the funds. During the current financial year, the Company recognised an impairment loss of S\$78,091 (2024: S\$29,829) and made a reversal of a previously recognised impairment loss of S\$96,709 (2024: S\$471,835) for the investments in financial assets.

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 4 Income from Generated Funds – Voluntary Income

income irom Generated Funds – voluntary income		
	<u>2025</u>	<u>2024</u>
		S\$
Unrestricted Funds:		·
Donations - in cash	3,145,161	3,495,169
Donations - in kind	13,621	11,878
Total donations - unrestricted	3,158,782	3,507,047
Others		
- Intermediate and Long-Term Care (ILTC) manpower initiatives	1,595,999	1,178,871
- Home Intervention	827,741	899,868
- Aged Care transition project	445,220	259,861
- Others	322,012	330,750
Total grants – unrestricted	3,190,972	2,669,350
Total unrestricted funds	6,349,754	6 176 207
Total unrestricted lunds	0,349,734	6,176,397
Restricted Funds:		
Donations	635,886	469,049
Grants:		
- Community Silver Trust fund	4,537,456	6,314,670
- Chaplaincy fund	603	761
- Medifund	23,700	18,200
- Patient welfare fund	3,687	15,861
- Financial Assistance Scheme	9,000	2,100
- Senior mobility fund	637,216	551,174
Total grants – restricted	5,211,662	6,902,766
- Total restricted funds	5,847,548	7,371,815
Total income from generated funds – voluntary income	12,197,302	13,548,212

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

_			
5	Income from Generated Funds – Activities for Generating Funds	<u>2025</u>	<u>2024</u>
		<u>2023</u> S\$	S\$
	Unrestricted Funds:	Бф	Эψ
	Fundraising:		
	- Silver Anniversary	891,078	1,965,115
	- Christmas appeal	63,635	40,022
	- Wesley Easter	176,217	277,413
	- Chinese New Year	23,910	47,497
	- Others	107,578	318,285
	Total income from generated funds – activities for generating funds	1,262,418	2,648,332
6	Income from Generated Funds – Investment Income		
		<u>2025</u>	<u>2024</u>
		S\$	S\$
	Unrestricted Funds:		
	Dividend from investments in financial assets	26,147	18,114
	Reversal of impairment loss on investments in financial assets		
	(Note 16)	96,709	471,835
	Interest:		
	- Bank balances	983,989	809,090
	- Investments in financial assets	724,368	517,237
	Gain on disposal on investments in financial assets	76,000	34,365
	Total unrestricted funds	1,907,213	1,850,641
	Restricted Funds:		
	Interest - Bank balances	93,845	130,313
	Total income from generated funds – investment income	2,001,058	1,980,954

During the financial year ended 31 March 2025, an amount of \$\$1,474,506 (2024: \$\$1,410,823), \$\$156,683 (2024: \$\$186,569), \$\$167,517 (2024: \$\$133,406), \$\$84,977 (2024: \$\$101,944) and \$\$23,530 (2024: \$\$17,899) have been allocated to the "unrestricted funds", "asset replacement fund", "new project fund", "talent management fund" and "bicentennial community fund", respectively.

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

8

income from Charleague Activities	2025	2024
	<u>S</u> \$	<u></u>
Unrestricted Funds:	·	·
Ward charges	10,537,029	10,466,325
Treatment charges	3,654,096	3,717,927
Rehabilitation charges	4,258,447	3,858,937
Day rehabilitation and outpatient clinic	1,719,201	1,481,546
Procedures and investigations	1,199,631	1,103,383
Pharmaceuticals	1,013,665	1,011,606
Consumables	890,188	700,540
Home care and home assessments	731,849	720,359
Ambulance and others services	432,551	447,163
X-ray services	53,203	57,046
Government subventions:		
- Rehabilitation	26,683,928	24,688,826
- Day rehabilitation and home care	2,258,349	1,928,477
- Inpatient Hospice Palliative Care Service	3,067,585	2,062,641
Hospital subsidies and discounts	(3,937,692)	(4,849,846)
Government grant:		
- Land lease rental	876,100	876,100
- Community Care Salary Enhancement grant	7,961,718	6,556,951
Total income from charitable activities	61,399,848	54,827,981
Other Income		
other meome	2025	2024
	<u>2023</u> S\$	S\$
Unrestricted Funds:	υψ	Бψ
Training and course fees	1,960,748	2,007,699
Professional service fees	381,778	346,687
Parking fees	98,843	90,817
Others	128,808	94,867
	2,570,177	2,540,070
Restricted Funds:		
Others	428	109,458
Total other income	2,570,605	2,649,528

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## **9** Costs of Generating Funds

Costs of Generating Funus		
	<u>2025</u>	<u>2024</u>
	S\$	S\$
Unrestricted Funds:		
Voluntary income		
Direct operating costs	29,651	30,650
Support costs		
- Salaries and related costs (Note 13)	382,636	285,654
- Depreciation (Note 15)	24,174	23,104
- Amortisation (Note 15)	(12,691)	(11,965)
- Land lease rental	4,156	3,813
- Others	100,775	74,846
	528,701	406,102
Fundraising activities		
Direct operating costs	196,805	146,603
Total costs of generating funds	725,506	552,705
	-	<u> </u>

The support costs of the Company which include office functions such as key and general management are apportioned based on the amount of time spent, floor area occupied and the number of staff operating in the Company.

#### 10 Charitable Activities

	<u>2025</u>	<u>2024</u>
	S\$	S\$
Unrestricted Funds:		
<u>Direct operating costs</u>		
Salaries and related costs (Note 13)	39,551,944	36,924,946
Professional services		
- Medical & Allied Health services	1,665,570	1,680,783
- Nursing & Therapist services	653,242	828,673
Catering	1,393,912	1,197,744
Pharmaceuticals (Note 12)	920,092	983,290
Consumables (Note 12)	1,118,168	1,042,108
Laundry services	231,100	230,840
Laboratory	423,584	450,712
X-ray	134,104	132,516
Epidemic expenses	154,589	190,419
Ambulance and others	602,869	569,630
	46,849,174	44,231,661

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 10 Charitable Activities (cont'd)

Chartable Activities (cont d)		
	<u>2025</u>	<u>2024</u>
	S\$	S\$
Unrestricted Funds: (cont'd)		
<u>Indirect operating costs</u>		
Salaries and related costs (Note 13)	6,482,766	5,716,716
Building maintenance	2,466,550	2,395,507
Depreciation (Note 15)	5,302,271	5,073,725
Amortisation (Note 15)	(2,795,411)	(2,630,367)
Land lease rental	911,519	836,255
Repair and maintenance	734,758	487,531
Utilities	799,692	744,343
GST input tax disallowed	1,386,049	965,612
Security expenses	238,002	229,178
Publicity expenses	48,863	111,147
IT maintenance	1,950,970	1,566,001
Others	1,704,744	1,300,517
	19,230,773	16,796,165
	66,079,947	61,027,826
Restricted Funds:		
Financial aid for needy patients	756,230	680,360
Salaries and related costs (Note 13)	763,360	355,127
Other operating costs	903,747	327,636
Utilisation of Community Silver Trust fund	,	,
- Salaries and related costs (Note 13)	2,506,603	2,447,960
•	4,929,940	3,811,083
	<del>_</del>	
Total costs of charitable activities	71,009,887	64,838,909

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 11 Governance Costs and Other Expenditures

Governance Costs and Other Expenditures		
•	<u>2025</u>	<u>2024</u>
	S\$	S\$
Governance costs		
Unrestricted Funds:		
Salaries and related costs (Note 13)	1,289,052	1,148,248
Building maintenance	28,114	27,304
Depreciation (Note 15)	60,434	57,762
Amortisation (Note 15)	(31,727)	(29,913)
Repair and maintenance	30,472	18,611
Utilities	9,115	8,484
GST input tax disallowed	57,485	36,863
Land lease rental	10,389	9,532
Others	122,097	91,630
Audit fees		
- Statutory audit	50,000	45,000
- Certification audit	16,500	15,500
Other professional fees	260,509	157,979
Total governance costs	1,902,440	1,587,000
Other expenditure		
Impairment loss on investments in financial assets (Note 12)	78,091	29,829
Investment expenses	102,021	98,298
Loss on written off of property, plant and equipment	1,701	281
	181,813	128,408

## 12 Net Income before Tax Expense

This was arrived at after charging/(crediting) to the statement of financial activities:

	<u>2025</u>	<u>2024</u>
	S\$	S\$
Cost of inventories sold (included in charitable activities		
expenses)		
- Pharmaceuticals (Note 10)	920,092	983,290
- Consumables (Note 10)	1,118,168	1,042,108
Land lease rental	926,064	849,600
Operating lease rental - equipment rental expenses	75,771	24,115
Depreciation expenses (Note 15)	5,386,879	5,154,591
Amortisation expenses (Note 15)	(2,839,829)	(2,672,245)
Impairment loss on investments in financial assets (Note 11)	78,091	29,829
Reversal of impairment loss on investments in financial assets		
(Note 6)	(96,709)	(471,835)
Bad debt written off	1,792	1,376
Provision for doubtful debts (Note 17)	44,882	4,416
Write back of provision for doubtful debts (Note 17)	(1,782)	(51)
Loss on written off of property, plant and equipment	1,701	281

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

13	Employee Benefits	2025	2024
	Unrestricted Funds:	<u>2025</u> S\$	<u>202 :</u> S\$
	Included in Direct Operating Costs of Charitable Activities:	*	•
	Salaries and related costs		
	Short-term employee benefits:		
	- Gross salaries and bonuses	33,772,517	31,358,478
	- Foreign workers' levy	1,363,200	1,262,401
	- Other staff benefits	1,144,987	1,173,338
	Post-employment benefits (Defined Contribution Plans)	3,271,240	3,130,729
	Total salaries and related costs (Note 10)	39,551,944	36,924,946
	Included in Costs of Generating Funds, Indirect Operating Costs of Charitable Activities and Governance Costs (Notes 9, 10 and 11): Salaries and related costs		
	Short-term employee benefits:		
	- Gross salaries and bonuses	6,850,642	5,967,725
	- Foreign workers' levy	28,551	26,042
	- Other staff benefits	512,109	463,143
	Post-employment benefits (Defined Contribution Plans)	763,152	693,708
	Total salaries and related costs	8,154,454	7,150,618
	Included in Charitable Activities – Restricted Funds:  Salaries and related costs  Short-term employee benefits: - Gross salaries and bonuses	2,843,729	2,438,954
	- Other staff benefits	75,958	91,990
	Post-employment benefits (Defined Contribution Plans)	350,276	272,143
	Total salaries and related costs (Note 10)	3,269,963	2,803,087
	Total employee benefits	50,976,361	46,878,651
	N. 1. C. 1. (21.W. 1	574	5.45
	Number of employees as at 31 March	574	545
	Top three highest paid employees in the following remuneration bands of:	<u>2025</u>	<u>2024</u>
	S\$500,001 to S\$600,000	2	1
	S\$400,001 to S\$500,000	1	2
	- -	3	3
	Common action of tan three high act waid any law are	2025 S\$	2024 S\$
	Compensation of top three highest paid employees: Salaries and bonuses	1 472 650	1 350 506
	Defined contribution plans (Employer CPF)	1,473,659 52,767	1,359,506 50,597
	Defined contribution plans (Employer CFF)	1,526,426	1,410,103
	-	1,320,420	1,410,103

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 13 Employee Benefits (cont'd)

Annual increment and bonuses are based on hospital achievements, financial considerations of the hospital and the individual employee performance with final decision at the sole discretion of Human Resource Committee/Board of Directors.

### 14 Tax Expense

The Company is an approved charity under the Charities Act 1994 ("Charities Act") and an Institution of a Public Character under the Income Tax Act 1947. No provision for taxation has been made in the financial statements as the Company is a registered charity with income tax exemption. As required by the Charities Act, the total fund-raising and sponsorship expenses of the Company for the financial years did not exceed 30% of the total gross receipts from fund-raising and sponsorship for the respective financial years.

### 15 Property, Plant and Equipment

i roperty, i iant and Equipment					
		Computers,			
		furniture		Building	
	Leasehold	and office	Hospital	under	
	<u>building</u>	<u>equipment</u>	<u>equipment</u>	construction	<u>Total</u>
	S\$	S\$	S\$	S\$	S\$
2025					
Cost					
At 1 April 2024	53,039,823	5,055,248	5,892,417	-	63,987,488
Additions	1,106,902	839,285	250,805	815,837	3,012,829
Write-off	-	(493,996)	(553,066)	-	(1,047,062)
At 31 March 2025	54,146,725	5,400,537	5,590,156	815,837	65,953,255
Less: Accumulated depreciation					
At 1 April 2024	42,400,019	3,328,494	5,292,793	-	51,021,306
Depreciation for the year	4,326,092	780,557	280,230	-	5,386,879
Write-off	-	(493,697)	(551,664)	-	(1,045,361)
At 31 March 2025	46,726,111	3,615,354	5,021,359	-	55,362,824
Net carrying amount					
At 31 March 2025	7,420,614	1,785,183	568,797	815,837	10,590,431
2024					
2024					
Cost	50.075.026	4.000.756	5 701 012	001 (20	(1 (50 124
At 1 April 2023	50,875,926	4,089,756	5,701,813	991,629	61,659,124
Additions	-	515,242	277,356	2,226,658	3,019,256
Write-off	2 1 62 007	(604,140)	(86,752)	(2.210.207)	(690,892)
Transfer	2,163,897	1,054,390	5.002.415	(3,218,287)	- (2.007.400
At 31 March 2024	53,039,823	5,055,248	5,892,417	-	63,987,488
Less: Accumulated depreciation					
At 1 April 2023	38,207,624	3,197,085	5,152,617	-	46,557,326
Depreciation for the year	4,192,395	735,268	226,928	-	5,154,591
Write-off	-	(603,859)	(86,752)	_	(690,611)
At 31 March 2024	42,400,019	3,328,494	5,292,793	-	51,021,306
Net carrying amount					
At 31 March 2024	10,639,804	1,726,754	599,624	_	12,966,182
——————————————————————————————————————		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·		

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 15 Property, Plant and Equipment (cont'd)

Net depreciation charged to the statement of financial activities as indirect operating costs are:

		2025	2024
			S\$
	Net depreciation charged to statement of financial activities:		
	Depreciation for the year	5,386,879	5,154,591
	Amortisation of new project fund (Note 20)	(11,969)	(5,972)
	Amortisation of building fund (Note 21(i))	(427,156)	(427,153)
	Amortisation of building expansion fund (Note 21(ii))	(1,678,822)	(1,606,080)
	Amortisation of Community Silver Trust capital grant (Note		
	21(iv))	(721,882)	(633,040)
		(2,839,829)	(2,672,245)
	Net depreciation of property, plant and equipment	2,547,050	2,482,346
4.2			
16	Investments in Financial Assets	2025	2024
		<u>2025</u>	<u>2024</u>
	C1 'C 1	S\$	S\$
	Classified as: Non-current investments	1 005 500	1 005 500
	Current investments	1,005,500	1,005,500
	Current investments	26,510,324	22,177,206
		27,515,824	23,182,706
	Cost	22 207 570	21 177 126
	Balance at the beginning of the year	23,386,578	21,177,126
	Acquisitions	19,804,655	13,662,412
	Disposals  Redemention of debt accomities	(3,425,079)	(2,552,960)
	Redemption of debt securities Balance at the end of the year	<u>(12,100,000)</u> 27,666,154	(8,900,000) 23,386,578
	barance at the end of the year	27,000,134	23,380,378
	Less: Accumulated impairment loss		
	Balance at the beginning of the year	203,872	702,979
	Impairment loss (Note 11)	78,091	29,829
	Reversal of impairment loss (Note 6)	(96,709)	(471,835)
	Disposals	(34,924)	(57,101)
	Balance at the end of the year	150,330	203,872
	Net investments in financial assets	27,515,824	23,182,706
	Market values	28,258,497	23,577,535
			· , ,

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 16 Investments in Financial Assets (cont'd)

<u>2025</u>	<u>2024</u>
S\$	S\$
18,468,692	14,528,643
456,249	-
1,487,737	1,575,733
6,991,000	6,962,093
112,146	116,237
27,515,824	23,182,706
	S\$  18,468,692  456,249 1,487,737 6,991,000 112,146

The effective interest rate for the interest-bearing financial assets, primarily debt investments, is 3.8% (2024: 3.93%).

During the financial year ended 31 March 2025, an impairment loss of \$\$78,091 (2024: \$\$29,829) for certain investments in financial assets was provided as management assessed that there was objective evidence of impairment in the investments in financial assets. The Company reversed an impairment loss of \$\$96,709 (2024: \$\$471,835) for certain investments in financial assets due to the recovery of these investments previously provided for.

#### 17 Trade and Other Receivables

	<u>2025</u>	<u>2024</u>
	S\$	S\$
Trade Receivables		
Patient's fees	2,651,578	3,269,180
Less: Provision for doubtful debts	(44,882)	(4,416)
	2,606,696	3,264,764
Other Receivables		
Community Silver Trust funds receivables	10,852,126	11,724,227
Government grants receivables	4,399,057	3,871,971
Other receivables	151,765	384,566
Interest receivable	251,063	158,073
Deposits	10,900	10,339
_	15,664,911	16,149,176
Prepayments	475,730	434,917
Total trade and other receivables	18,747,337	19,848,857

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 17 Trade and Other Receivables (cont'd)

Trade receivables are stated net of provision for doubtful debts. Provision for doubtful debts is analysed as follows:

	2025 S\$	2024 S\$
Balance at the beginning of the year Provision for doubtful debts recognised during the year	4,416	2,138
(Note 12)	44,882	4,416
Write back of provision for doubtful debts (Note 12) Write off against provision for doubtful debts	(1,782) (2,634)	(51) (2,087)
Balance at the end of the year	44,882	4,416

Trade receivables that are determined to be impaired at the reporting date relates to the debtors that are in financial difficulties or have defaulted on payments.

During the financial year ended 31 March 2025, the Company recovered an amount of S\$1,782 (2024: S\$51) which had been previously provided for, and accordingly, these have been written back during the financial year. A provision for doubtful debts of S\$44,882 (2024: S\$4,416) has been made for the financial year ended 31 March 2025 as the recovery of these amounts was considered doubtful. Bad debt written off of S\$1,792 (2024: S\$1,376) has been expensed during the current financial year.

#### 18 Cash and Cash Equivalents

•	2025 S\$	2024 S\$
Fixed deposits placed with financial institutions	40,081,491	35,455,433
Cash and bank balances	5,471,928	4,779,007
Cash and cash equivalents per statement of cash flows	45,553,419	40,234,440

The weighted average effective interest rate earned on fixed deposits is 3.12% (2024: 3.35%) per annum with maturity dates ranging from 1 month to 12 months (2024: 3 to 12 months).

Included in the cash and cash equivalents are \$\$17,551,187 (2024: \$\$14,372,130) classified to "designated unrestricted funds" and \$\$408,674 (2024: negative \$\$217,272) classified to "restricted funds" of which the use is subject to relevant restricted funds' operating terms.

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 19 Trade and Other Payables

Trade and Other rayables	2025	2024
	2025 S\$	<u>2024</u> S\$
Current	5.0	БФ
Trade Payables		
Trade payables	1,965,289	1,886,317
Other Payables		
Accrued IT expenses	1,159,683	827,640
Accrued staff costs	9,531,854	7,985,228
CPF payables	1,495,637	1,375,615
Other creditors	1,556,158	404,893
Claw back of government subsidy	1,084,186	1,549,999
Other accruals	1,332,721	1,394,385
	16,160,239	13,537,760
	18,125,528	15,424,077

The Company has claw back of government subsidies of \$\$1,084,186 (2024: \$\$1,549,999) which arises from overlap in government subvention of Ministry of Health ("MOH")'s initiatives for Transitional Care Facility. An amount of \$\$465,813 related to Hip Fracture Project partnering with National University Hospital ("NUH") in 2024 was reversed during the current financial year.

#### **20** Unrestricted Funds

		2025 S\$	2024 S\$
Unrestricted income funds	(i) _	51,000,571	47,776,910
Designated funds:			
- Asset replacement fund	(ii)	6,511,605	6,354,922
- New project fund	(iii)	7,430,542	5,274,994
- Talent management fund	(iv)	3,243,711	2,324,315
- Bicentennial community fund	(v)	365,329	417,899
Total designated funds	-	17,551,187	14,372,130
Total unrestricted funds	_	68,551,758	62,149,040

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 20 Unrestricted Funds (cont'd)

- (i) The unrestricted income funds are available to the Company to apply for the general purposes of the charity as set out in its governing document.
- (ii) Asset replacement fund is set up to finance future system upgrading and replacement.
- (iii) The new project fund is available to the Company for future new project requirements.
- (iv) Talent management fund is set-up during the year and will be used to attract, retain and develop professional competencies of healthcare professionals.
- (v) Bicentennial community fund is set up to encourage all to embrace the spirit of SG Cares by giving back to community as part of the Singapore Bicentennial commemoration.

Movements of the unrestricted funds during the financial year are disclosed as follows:

	2025 S\$	2024 S\$
Funds balance at the beginning of the year	62,149,040	54,881,662
Total income	73,489,410	68,043,421
Total expenditure	(68,889,706)	(63,295,939)
Net income	4,599,704	4,747,482
Gross transfers between funds: - Transfer from Community Silver Trust Fund (Note 21(iii))	1,814,983	2,525,868
Amortisation expenses net of depreciation of property, plant and equipment credited to charitable activities (Note 15)	(11,969)	(5,972)
Funds balance at the end of the year	68,551,758	62,149,040

During the financial years ended 31 March 2025 and 2024, the Company is allowed to claim its recurrent operating expenses under the Community Silver Trust matching grant up to 40% of the donations received and channelled to ILTC services in the prevailing financial year. The Company has 5 years to utilise the funds for projects. During the financial year ended 31 March 2025, the Company transferred from the Community Silver Trust fund an amount of S\$1,814,983 (2024: S\$2,525,868) to utilise for recurrent operating expenses.

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 21 Restricted Funds – Restricted Income Funds

		<u>2025</u>	<u>2024</u>
		S\$	S\$
Restricted income funds:			
- Building fund – General	(i)	605,133	1,032,289
- Building expansion fund	(ii)	3,149,387	4,215,169
- Community Silver Trust fund	(iii)	9,857,129	10,621,609
- Community Silver Trust capital grant	(iv)	1,084,837	1,528,106
- Other funds	(v) _	1,257,376	1,474,416
Total restricted income funds		15,953,862	18,871,589

Movements of the restricted income funds during the financial year are disclosed as follows:

	<u>2025</u>	<u>2024</u>
	S\$	S\$
Funds balance at the beginning of the year	18,871,589	19,964,691
	, ,	, ,
Total income	5,941,821	7,611,586
Total expenditures (Note 10)	(4,929,940)	(3,811,083)
Net income	1,011,881	3,800,503
Net transfers between funds	(1,814,983)	(2,525,868)
Grant income	713,235	298,536
Amortisation expenses net of depreciation of property, plant		
and equipment credited to charitable activities (Note 15)	(2,827,860)	(2,666,273)
Face 1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	15.052.062	10 071 500
Funds balance at the end of the year	15,953,862	18,871,589
() P-11: - f-1 C1		
(i) Building fund – General	2025	2024
	2025 S\$	2024 S\$
	Эф	သမှ
Balance at the beginning and end of the year	13,045,322	13,045,322
Less: Amount amortised:		
Balance at the beginning of the year	12,013,033	11,585,880
Amortisation for the year (Note 15)	427,156	427,153
Balance at the end of the year	12,440,189	12,013,033
N. 1. 1 1 1 1.	60 <b>m</b> 166	1 000 000
Net balance at the end of the year	605,133	1,032,289

These are capital grants received from MOH and donations received from the public for the building of the hospital for the Company. These amounts are amortised to net off the corresponding depreciation in the statement of financial activities.

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 21 Restricted Funds – Restricted Income Funds (cont'd)

(ii) Building expansion fund		
	<u> 2025</u>	2024
	S\$	S\$
Balance at the beginning of the year	19,259,831	18,961,295
Grants received/receivable	613,040	298,536
Balance at the end of the year	19,872,871	19,259,831
Less: Amount amortised:		
Balance at the beginning of the year	15,044,662	13,438,582
Amortisation for the year (Note 15)	1,678,822	1,606,080
Balance at the end of the year	16,723,484	15,044,662
Net balance at the end of the year	3,149,387	4,215,169
•		

These are grants received/receivable from MOH for the building expansion. The Company recognised the grants in the statement of financial activities at the point when it has entitlement to the income. These amounts are amortised to net off the corresponding depreciation in the statement of financial activities.

(iii) Community Silver Trust fund		
	<u>2025</u>	<u>2024</u>
	S\$	S\$
Balance at the beginning of the year	10,621,609	9,483,044
Add: Income		
Community Silver Trust Matching Grant	4,537,456	6,314,670
Investment income - interest income	43,656	87,415
Less: Expenditures	(3,352,191)	(2,701,691)
Net income	1,228,921	3,700,394
Gross transfers between funds:		
- Transfer to unrestricted funds (Note 20)	(1,814,983)	(2,525,868)
- Transfer to Community Silver Trust capital grant (Note		
21(iv))	(178,418)	(35,961)
Balance at the end of the year	9,857,129	10,621,609

These are dollar-for-dollar donation matching grants provided by MOH through Agency for Integrated Care ("AIC") to enhance the services of voluntary welfare organisations ("VWOs") in the intermediate and long-term care ("ILTC") sector for eligible donations received by the Company.

During the financial year ended 31 March 2025, the Company recognised matching grant income of S\$4,537,456 (2024: S\$6,314,670), being eligible donation income earned during the financial years, which met the terms and conditions under the agreement of the matching grant.

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 21 Restricted Funds – Restricted Income Funds (cont'd)

Community Silver Trust capital grant

	2025 S\$	2024 S\$
Balance at the beginning of the year	1,528,106	2,125,185
Grants received	100,195	-

Gross transfers between funds:
- Transfer from Community Silver Trust fund (Note 21(iii))

178,418

35,961

Amortisation for the year (Note 15) (721,882) (633,040)

Balance at the end of the year 1,084,837 1,528,106

The Community Silver Trust capital grant was set up from the Community Silver Trust fund for the purpose of capitalising the fixed assets purchased with the fund proceeds. These amounts are amortised to net-off the corresponding depreciation in the statement of financial activities.

#### (v) Other Funds

(iv)

			Restricte	ed Funds			
			Financial				
			Assistance		Patient	Senior	Total
1 April 2024 to 31 March 2025	Chaplaincy(a)	Medifund <sup>(b)</sup>	Scheme(b)	Memorial(c)	Welfare <sup>(d)</sup>	Mobility <sup>(e)</sup>	<u>funds</u>
	S\$	S\$	S\$	S\$	S\$	S\$	S\$
Income							
Income from generated funds:							
Voluntary income	506,612	23,700	9,000	-	133,564	637,216	1,310,092
Investment income - interest							
income	47,126	45	-	2,926	92	-	50,189
Other income		-	_	-	428	-	428
Total income	553,738	23,745	9,000	2,926	134,084	637,216	1,360,709
Less: Expenditures							
Charitable activities	778,482	27,541	8,281		101,029	662,416	1,577,749
Total expenditures	778,482	27,541	8,281		101,029	662,416	1,577,749
Total expeliditures	170,402	27,341	0,201		101,029	002,410	1,377,749
Net (expenditure)/income							
before tax expense	(224,744)	(3,796)	719	2,926	33,055	(25,200)	(217,040)
Transfer between funds		-	-	-	-	-	
Net (expenditure)/income after							
funds transfer	(224,744)	(3,796)	719	2,926	33,055	(25,200)	(217,040)
Total funds brought forward	1,166,278	86,259	2,100	110,784	(243)	109,238	1,474,416
Amortisation of expenses net of depreciation of property, plant and equipment credited to charitable activities expenses	_	_	_	_	_	_	_
Total funds carried forward	941,534	82,463	2.819	113,710	32.812	84.038	1,257,376
		,_,	-,	,,	,	- 1,000	, ,

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 21 Restricted Funds – Restricted Income Funds (cont'd)

#### (v) Other Funds (cont'd)

			Restricte	ed Funds			
			Financial				
			Assistance		Patient	Senior	Total
1 April 2023 to 31 March 2024	Chaplaincy <sup>(a)</sup>	Medifund(b)	Scheme(b)	Memorial <sup>(c)</sup>	Welfare(d)	Mobility(e)	<u>funds</u>
	S\$	S\$	S\$	S\$	S\$	S\$	S\$
Income							
Income from generated funds:							
Voluntary income	298,641	18,200	2,100	-	187,030	551,174	1,057,145
Investment income - interest							
income	40,233	51	-	2,576	38	_	42,898
Other income	108,927	3	-	-	528	-	109,458
Total income	447,801	18,254	2,100	2,576	187,596	551,174	1,209,501
Less: Expenditures							
Charitable activities	363,509	42,655	_	_	106,444	596,784	1,109,392
Total expenditures	363,509	42,655	-	-	106,444	596,784	1,109,392
Net income/(expenditure)							
before tax expense	84,292	(24,401)	2,100	2,576	81,152	(45,610)	100,109
Transfer between funds	04,272	(24,401)	2,100	2,370	01,132	(43,010)	100,107
Net income/(expenditure) after							
funds transfer	84,292	(24,401)	2,100	2,576	81,152	(45,610)	100,109
Total funds brought forward	1,081,986	110,660		108,208	(81,395)	154,848	1,374,307
Total funds brought for ward	1,061,960	110,000	-	100,200	(61,393)	134,040	1,374,307
Amortisation of expenses net of depreciation of property, plant and equipment credited to							
charitable activities expenses		-	-	-	-	-	
Total funds carried forward	1,166,278	86,259	2,100	110,784	(243)	109,238	1,474,416

- (a) Chaplaincy fund was set up to finance the chaplaincy ministry in the Hospital.
- (b) Medifund and Financial Assistance Scheme is funded by MOH to pay the fees of needy patients.
- (c) Memorial fund was set up in memory of Mr and Mrs Lee Teck Hock. Monies in the fund are placed in fixed deposits and only the interest earned was used to finance the Hospital's operating expenditure.
- (d) Patient welfare fund was set up for the purpose specified from the donors to help those patients in financial hardship.
- (e) Senior mobility fund is funded by MOH to purchase mobile friendly equipment and daily consumables for needy patients.

Donations of S\$506,009 (2024: S\$297,880) and S\$129,877 (2024: S\$171,169) are included in Chaplaincy – Voluntary Income and Patient Welfare - Voluntary Income, respectively.

#### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

#### 22 Related Party Transactions

Related parties may be individuals or corporate entities.

- (a) Parties are considered to be related if an individual or a close member of that individual's family is related to a Company if that individual (i) has control or joint control over the Company; (ii) has significant influence over the Company; or (iii) is a governing board member, trustee, or member of the key management personnel of the Company or of a parent of the Company.
- (b) Parties are also considered to be related if an entity is related to the Company if (i) the entity and the Company are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others; (ii) the Company is an associate or joint venture of the Company (or an associate or joint venture of a member of a group of which the charity is a member) and vice versa; (iii) the entity and the Company are joint ventures of the same third party; (iv) the entity is a joint venture of a third entity and the Company is an associate of the third entity and vice versa; (v) the entity is controlled or jointly controlled by a person identified in (a); and (vi) an individual identified in (a)(i) has significant influence over the entity or is a governing board member, trustee or member of the key management personnel of the entity (or of a parent of the Company).

There are no transactions with related parties during the current and previous financial years, except as disclosed in Note 25. The Company does not have any employees who are close family members of the Executive Head or Board members.

#### 23 Commitments

(a) Operating Lease Commitments

At the reporting date, the Company had no contingent rent, renewal or purchase options and escalation clauses, subleases, and restrictions imposed by lease arrangements. The future minimum lease payment under non-cancellable operating leases with an original term of more than one year of the Company is as follows:

	<u>2025</u>	<u>2024</u>
	S\$	S\$
Within one year	60,448	50,817
Between two to five years	100,992	153,305
	161,440	204,122

The operating lease payment is for rental payable in respect of operating lease of office equipment.

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 23 Commitments (cont'd)

#### (b) Capital Commitments

Capital expenditure contracted for or approved at the reporting date but not recognised in the financial statements is as follows:

	<u>2025</u>	<u>2024</u>
	S\$	S\$
Building, furniture and equipment	3,098,919	232,316

#### **24** Donations Schedule

The Company is approved as an Institution of a Public Character ("IPC") under the provision of the Income Tax Act. Donors to the Company are granted tax deduction.

	<u>2025</u>	<u>2024</u>
	S\$	S\$
Tax deductible donations	4,273,855	5,728,733
Non tax-deductible donations	769,610	883,817
Non tax-deductible donations in kind	13,621	11,878
Total donations (i)	5,057,086	6,624,428

(i) The total donations comprised of donations from voluntary income and fundraising from activities for generating funds of S\$3,794,668 (2024: S\$3,976,096) and S\$1,262,418 (2024: S\$2,648,332) as disclosed in Notes 4 and 5, respectively.

#### 25 Key Management Remuneration

	<u>2025</u>	<u>2024</u>
Number of key management personnel in the following		
remuneration bands of:		
S\$500,001 to S\$600,000	2	1
S\$400,001 to S\$500,000	-	1
S\$200,001 to S\$300,000	1	1
	3	3
	<u>2025</u>	<u>2024</u>
	S\$	S\$
Compensation of key management personnel:		
Salaries and bonuses	1,343,813	1,234,647
Defined contribution plans (Employer CPF)	45,984	40,953
• • • •	1,389,797	1,275,600

### NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2025

## 25 Key Management Remuneration (cont'd)

None of the directors of the Company and close members of the governing board member's family receive any remuneration, benefits, allowances or other manner of compensation for the financial years ended 31 March 2025 and 2024.

## 26 Reserve Policy

As set out in the Directors' Statement, the Board has established a reserve policy for the Company. The reserve measurement is calculated as follows:

	2025 S\$	2024 S\$
Unrestricted funds (Reserves)	68,551,758	62,149,040
Net liquid assets available to meet expenditure obligations	63,100,974	56,270,323
Total operating expenditure (Unrestricted funds)	68,889,706	63,295,939
Ratio of net liquid assets to total operating expenditure	0.92	0.89

The Company does not have any externally imposed capital requirements for the financial years ended 31 March 2025 and 2024. There were no changes in the Company's reserve policy during the financial years ended 31 March 2025 and 2024.